NICE says it is not cost effective. When the UK government won't cover or subsidize the cost of Sativex, then MS sufferers can't afford it. That translates into a lot of loss revenue for GW in the UK.
Pure and simple, we need FDA approval in the U.S. to generate revenue. GW can't continue issuing more shares. That's not a viable strategy.
News 
Market Data 
Discover 
